Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value - Jim Martin, Co-CEO and CFO, Cocrystal Pharma, Inc. 00:00:00

Share On Facebook Share On Twitter

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2) noroviruses and hepatitis C viruses.

Recent Videos